Brief: HCW Biologics Discovers That HCW11-040 Prevents Bronchopulmonary Dysplasia During IND-Enabling Studies
14/05/2026 12:32
May 14 (Reuters) - HCW Biologics Inc HCWB.O: HCW BIOLOGICS DISCOVERS THAT HCW11-040 PREVENTS BRONCHOPULMONARY DYSPLASIA (BPD) DURING IND-ENABLING STUDIES HCW BIOLOGICS INC - EXPECTS TO COMPLETE IND-ENABLING STUDIES IN H2 2027 AND FILE IND APPLICATION FOR HCW11-040 Source text: ID:nGNX7jwMkY Further company coverage: HCWB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: HCW Biologics Proposed Resale Of Up To 5.69 Million Shares Of Common Stock
Brief: HCW Biologics To Regain Full Rights For Two Commercial-Ready Reagents From Wugen
Brief: HCW Biologics Prices Private Placement Of 2.8 Mln Units At $1.405 Per Unit
NASDAQ RESUMED AT 09:59 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:54 AM